
HeartFlow Inc (HTFL) Stock Forecast & Price Target
HeartFlow Inc (HTFL) Analyst Ratings
Bulls say
HeartFlow Inc. demonstrated a strong performance in 3Q25, with revenues reaching $46.3 million—a 41% year-over-year increase—driven primarily by the uptake of its FFR-CT coronary disease analysis software. Gross margins impressively improved to 76.8%, indicating enhanced profitability and operational efficiency. Additionally, the fundamentals of the core business are solid, as evidenced by robust volume growth, expanding adoption of coronary CT angiography, and the anticipation of future revenue contributions from plaque analysis, positioning the company for sustained mid-20s revenue growth moving forward.
Bears say
HeartFlow Inc has sustained substantial net losses since its inception, with $95.7 million in FY23 and $96.4 million in FY24, contributing to an uncertain profitability outlook as the company anticipates incurring further losses moving forward. The adoption of HeartFlow's diagnostic technology is contingent upon healthcare providers adhering to specific guidelines from the ACC and AHA, which may not be universally adopted. Additionally, the company faces reimbursement risks; inadequate coverage from third-party payors could significantly hinder the adoption of its platform, thus adversely impacting its financial position and growth prospects.
This aggregate rating is based on analysts' research of HeartFlow Inc and is not a guaranteed prediction by Public.com or investment advice.
HeartFlow Inc (HTFL) Analyst Forecast & Price Prediction
Start investing in HeartFlow Inc (HTFL)
Order type
Buy in
Order amount
Est. shares
0 shares